Extended Data Fig. 7: Effects of Dexa treatment in circulating FRFs, TMX-induced uteri hyperplasia and PD-L1 expression levels in several immune-populations.
From: Fasting boosts breast cancer therapy efficacy via glucocorticoid activation
a. MCF7 xenografts tumours volume in six-eight-week old female athymic nude mice treated with the depicted conditions (Control n = 7; TMX n = 7, Fasting n = 8; TMX+Fasting n = 8). After one month, all treatments were stopped and tumours were allowed to grow. Data are shown as mean ± SEM. b. Fold-change differences to basal conditions of circulating c-peptide, leptin and IGF-1 (FRFs) levels in in six-eight-week old female athymic nude mice xenografted with MCF7 cells, treated with the respective depicted conditions. Control n = 4, TMX n = 4, Fasting n = 4, TMX+Fasting n = 6, Dexa n = 4, TMX+Dexa n = 4. n, number of mice per treatment group. Data are shown as mean ± SD and analysed by two-tailed Student t-test. c. Microphotographs of H&E staining of mouse uteri after TMX (left panel) and TMX + Dexa (right panel) treatments. Black arrows indicate luminal epithelia and blue arrows indicate glandular epithelia from the endometrium. TMX n = 9, TMX+Dexa n = 8. n, represents different mice uteri analysed. d. TSAE1-engrafted tumour growth in immune-competent mice treated with either TMX alone (n = 17) or combined with Dexa (n = 19) for up to 26 days. n, number of tumours analysed. Data are shown as mean ± SEM and P-value is determined by mixed effect model. e. Body weight changes (%) in mice during the cycle treatments from the experiment performed in e. Data are shown as mean ± SD. TMX n = 10, TMX+Dexa n = 10. n, number of mice analysed. f. Bar plots showing the mean fluorescence intensity for selected markers for systemic myeloid cells and lymphoid cells (CD45 + CD11b+ and CD45 + CD11b- respectively), neutrophils (CD45 + CD11b + Ly6G + ), non-classical monocytes (CD45 + CD11b + Ly6G- Ly6C-) and dendritic cells (CD45 + F4/80- CD11c high MHCII high) from TSAE1-bearing mice treated with three rounds of control treatment, TMX, Dexa, or TMX+Dexa (7 days). Control n = 5, TMX n = 5, Dexa n = 5, TMX+Dexa n = 4. n, number of mice per treatment group. Data are shown as mean ± SD. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparison test.
